Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 334 (ZNF334) is a member of the C2H2 zinc finger family and contains a Kruppel-associated box domain, fourteen C2H2 zinc finger domains, and four C2H2-type/integrase DNA-binding domains[1][5]. It is primarily involved in transcriptional regulation as a DNA-binding transcription factor, mediating gene expression through interaction with nucleic acids[1][2][5][6]. Decreased expression of ZNF334 may serve as a biomarker for rheumatoid arthritis, and promoter methylation has been linked to the growth and development of cancers such as colorectal cancer[1][4]. There are currently no known approved drugs that specifically target ZNF334, and its role as a direct therapeutic target is not established in the literature[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 334 (ZNF334).